Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
14.89
+0.06 (0.40%)
At close: Oct 21, 2026, 4:00 PM EDT
15.09
+0.20 (1.34%)
Pre-market: Oct 22, 2026, 7:35 AM EDT
Cullinan Therapeutics Employees
Cullinan Therapeutics had 109 employees as of December 31, 2025. The number of employees decreased by 2 or 1.80% compared to the previous year. That makes Cullinan Therapeutics the 30,914th largest employer in the world and 3,949th in the United States.
Employees
109
Change (1Y)
-2
Growth (1Y)
-1.80%
Revenue / Employee
n/a
Profits / Employee
-$1,911,404
Market Cap
958.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 109 | -2 | -1.80% | 109 | 0 |
| Dec 31, 2024 | 111 | 26 | 30.59% | 111 | 0 |
| Dec 31, 2023 | 85 | 23 | 37.10% | 85 | 0 |
| Dec 31, 2022 | 62 | 31 | 100.00% | 62 | 0 |
| Mar 31, 2022 | 37 | 13 | 54.17% | 37 | 0 |
| Dec 31, 2021 | 31 | 7 | 29.17% | 31 | 0 |
| Sep 30, 2021 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2021 | 28 | 11 | 64.71% | 28 | 0 |
| Mar 31, 2021 | 24 | 7 | 41.18% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 393 |
| Rigel Pharmaceuticals | 174 |
| Monte Rosa Therapeutics | 173 |
| Odyssey Therapeutics | 100 |
| ArriVent BioPharma | 77 |
| SpyGlass Pharma | 76 |
| Alto Neuroscience | 68 |
| Jade Biosciences | 55 |
CGEM News
- 3 days ago - Cullinan: Zipalertinib demonstrates ‘clinically meaningful’ antitumor activity - TheFly
- 3 days ago - Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases - Business Wire
- 14 days ago - Cullinan Therapeutics doses first patient in CLN-049 trial - TheFly
- 14 days ago - Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 20 days ago - Cullinan Therapeutics initiates NDA for Zipalertinib - TheFly
- 20 days ago - New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program - GlobeNewsWire
- 27 days ago - Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright - TheFly
- 27 days ago - Cullinan Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts